Health Connect: Overview of biomedical infrastructure and policies in 11 cities of the Greater Bay Area

Under the overall blueprint and planning of the nation and the GBA, each city in the bay area introduced a series of policies and measures to keep align with the national policies to create conditions for development and improve the development environment, which, in turn forms a foundation for the city clusters in the GBA to collaborate and work together to reap mutual benefits to be enjoyed by all.

Mutual benefits shared in the GBA city cluster

With integration in the GBA, various major cities in the area are able to demonstrate their individual comparative advantages, achieve practical division of labor internally and foster joint development of the Biomedicine industry in the GBA mainly through optimizing the innovative deployment of the industry, deepening cooperation in special industries, increasing policy synergies, fostering joint construction of industrial park clusters an driving major scientific research and service platform construction.

In drug discovery and compound research in the Biomedicine industry, basic biomedicine research and flow of major innovative resources is fostered to meet the R&D and innovation requirements of biomedicine enterprises in the GBA driven by Guangzhou and Shenzhen and with the support of Zhuhai, Foshan and Zhongshan in the GBA, and the R&D advantage of Hong Kong Science and Technology Park in western medicines and of State Key Laboratory of Quality Research in Chinese Medicine in Macau. In terms of pre-clinical testing of the Biomedicine industry, large animal experimental bases in Jiangmen and Zhaoqing for regenerative medicine are leveraged to satisfy the pre-clinical studies and safety evaluation demand of biomedicine enterprises in the GBA. In terms of production of the Biomedicine industry, the southern China health care industrial bases in Jiangmen and Zhaoqing, and R&D and production bases in Huizhou and Dongguan are leveraged to satisfy the raw material supply demand of biomedicine enterprises in the GBA and to improve the conditions of drug production. The whole industrial chain may rely on the advantages of the financial centers in Hong Kong and Shenzhen and leverage the various financing methods, including listing in the mainland or overseas to provide room for expansion of development resources for enterprises in the GBA, and to achieve the objectives of sharing and reaping mutual benefits.